Michael M. Tarnow, President and Chief Executive Officer, joined the Company in July 1995 from Merck & Co., Inc. where he held the positions of Vice President Medco Containment Services and Merck Managed Care (1994-95); President and CEO of Merck Frosst Canada (1990-94); and Director of Corporate Development (1988-90). Mr. Tarnow received a JD from the University of Illinois.
Charles Cohen, PhD, Chief Scientific Officer, co-founded Creative BioMolecules in 1982. Dr. Cohen developed the Company's platform biology in understanding the role of morphogenic proteins in tissue formation. Dr. Cohen received his PhD in Basic Medical Science from New York University School of Medicine.
Carl M. Cohen, PhD, Vice President Research, joined the company in November 1997 from St-Elizabeth's Medical Center in Boston, Massachusetts, where held held the positions of Acting Chairman of the Department of Biomedical Research, and Chief of the Division of Cellular and Molecular Biology. Dr. Cohen received is PhD in Biophysics Research from Harvard University. Dr. Cohen is not related to Dr. Charles Cohen, the Company's founder and CSO.
Thomas J. Facklam, PhD, Vice President Product Development and Operations, joined the Company in May 1996 from Johnson & Johnson, where he held the position of Senior Director, International Project Management and Clinical Research at the R.W. Johnson Research Institute. Dr. Facklam received his PhD in Biochemistry/Molecular Biology from Ohio State University.
Gregory F. Liposky, Vice President Contract Manufacturing, joined the Company in March 1993 from Verax Corporation, a toll manufacturer of biotechnology products, where he held the position of Vice President, Bioprocessing. Mr. Liposky received his MBA from Monmouth College.
Cheryl K. Lawton, Vice President and General Counsel, joined the Company in January 1997 from MediSense, Inc., an international medical device manufacturing company, where she held the positions of Vice President (1996) and General Counsel (1995). In addition, she has held various legal positions and last served as Assistant General Counsel at Damon Corporation, a clinical laboratory service provider. Ms. Lawton received her JD from Suffolk University School of Law.
Steven L. Basta, Vice President Corporate Development and Investor Relations, joined the Company in February 1997. Mr. Basta has experience in the management of biotechnology development programs and the financing of biotechnology companies. Prior to joining the Company, he held several positions with The Immune Response Corporation, a biopharmaceutical company, including Executive Director of Product Development, and worked in corporate finance with Dillon Read and Co., Inc. Mr. Basta received his MBA from the Kellogg Graduate School of Management of Northwestern University.
Wayne E. Mayhew, III, Vice President and Chief Financial Officer, joined the Company in 1983 from Deloitte, Haskins & Sells where he held the position of Small Business Services and Audit Manager. Mr. Mayhew is a certified public accountant and received his Masters in Accounting from Brigham Young University.